Recent studies have presented that the pathophysiological mechanism of VTE in lung cancer patients is mainly due to the direct activation of coagulation by malignant cells through producing tissue factor (TF), cancer procoagulant (CP), cytokines, and inflammatory factors [27]. The gene discussed is F3; the disease is lung cancer.